CALIWAY BIOPHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment 2024-11-13 13:36
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction 2024-10-24 01:42
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease 2024-09-03 15:18
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention 2024-05-11 15:14
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints 2024-04-26 01:25
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease 2024-03-04 16:22
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease 2024-03-04 07:00
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 21:12
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 18:35
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease 2024-01-08 13:25
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024 2023-12-27 11:49
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction 2023-12-16 15:47
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study 2023-10-02 21:00
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment 2023-09-19 11:16
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7 2023-09-13 13:42
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite 2023-06-28 18:30
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction 2023-05-31 20:15
1